Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis

Abstract

Patients receiving PBT had significantly lower 5-year survival after curative-intent pancreatic surgery. Further research should focus on implementing guidelines for and discerning factors associated with the poor outcomes after PBT.

Impact of perioperative blood transfusion on clinical outcomes in patients with colorectal liver metastasis after hepatectomy: a meta-analysis

“…Since Burrows and Tartter first reported that PBT may worsen the postoperative survival of patients with bowel cancer in 1982 [31], a large number of authors have investigated the impact of PBT on clinical outcomes in patients with cancer subjected to surgery. In the field of hepatopancreaticobiliary oncological surgery, a meta-analysis of 23 studies reported that patients receiving PBT had significantly lower 5-year survival after curative-intent pancreatic surgery (OR, 2.43, 95% CI =1.90–3.10) [32]. Another meta-analysis of 22 studies noted that hepatocellular carcinoma patients receiving PBT had an increased risk of all-cause death at 3 and 5 years after surgery (respectively: OR = 1.92, 95% CI, 1.61-2.29; OR = 1.60, 95% CI, 1.47-1.73) compared with those without PBT [33].…”

Distance from Left Renal Vein to Inferior Pancreaticoduodenal Artery: A Landmark for Identifying Inferior Pancreaticoduodenal Artery in Pancreatoduodenectomy

“…Moreover, it is also reported that patients receiving perioperative blood transfusions have significantly worse postoperative outcomes in pancreatic cancer patients and that the surgical stress, which is increased by prolonged operative times, correlates with the cancer prognosis, suggesting potential prognostic impacts of the early ligation [6][7][8][9] . To enjoy the clinical usefulness of early ligation, it is necessary that IPDA, one of the major afferent arteries, be identified during PD.…”

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity

“…Previously, some studies have shown that patients with PDAC who receive a perioperative blood transfusion show a poorer prognosis. [28–30] In addition, intraoperative blood transfusions were shown to be an independent prognostic factor in PDAC. [31] Although the underlying mechanism remains unclear, blood transfusions have an immunosuppressive effect via transfusion-related immune modulation.…”